114 related articles for article (PubMed ID: 2495709)
21. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
Kasper W; Meinertz T; Hohnloser S; Engler H; Hasler C; Rössler W; Wolf H; Welzel D; Just H; Gurewich V
Klin Wochenschr; 1988; 66 Suppl 12():109-14. PubMed ID: 3126340
[TBL] [Abstract][Full Text] [Related]
22. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
von Hodenberg E; Kreuzer J; Hautmann M; Nordt T; Kübler W; Bode C
Am J Cardiol; 1991 Jun; 67(16):1349-53. PubMed ID: 1828324
[TBL] [Abstract][Full Text] [Related]
23. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
24. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
25. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
26. Clinical studies with the new glycosylated recombinant prourokinase.
Sasahara AA; Barker WM; Weaver WD; Hartmann J; Anderson JL; Reddy PS; Villiard EM
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):84S-93S. PubMed ID: 8770849
[TBL] [Abstract][Full Text] [Related]
27. Results of high dose intravenous urokinase for acute myocardial infarction.
Wall TC; Phillips HR; Stack RS; Mantell S; Aronson L; Boswick J; Sigmon K; DiMeo M; Chaplin D; Whitcomb D
Am J Cardiol; 1990 Jan; 65(3):124-31. PubMed ID: 2296881
[TBL] [Abstract][Full Text] [Related]
28. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
Ross AM; Gao R; Coyne KS; Chen J; Yao K; Yang Y; Qin X; Qiao S; Yao M;
Am Heart J; 2001 Aug; 142(2):244-7. PubMed ID: 11479462
[TBL] [Abstract][Full Text] [Related]
30. Effects of lipoprotein(a) on thrombolysis.
von Hodenberg E; Pestel E; Kreuzer J; Freitag M; Bode C
Chem Phys Lipids; 1994 Jan; 67-68():381-5. PubMed ID: 8187238
[TBL] [Abstract][Full Text] [Related]
31. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Van de Werf F; Nobuhara M; Collen D
Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts.
Denardo SJ; Morris NB; Rocha-Singh KJ; Curtis GP; Rubenson DS; Teirstein PS
Am J Cardiol; 1995 Oct; 76(11):776-80. PubMed ID: 7572653
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Susawa T; Yui Y; Hattori R; Takatsu Y; Yui N; Takahashi M; Aoyama T; Murohara Y; Shirotani M; Kawai C
Jpn Circ J; 1988 Jan; 52(1):72-8. PubMed ID: 3129601
[TBL] [Abstract][Full Text] [Related]
34. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
[TBL] [Abstract][Full Text] [Related]
35. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
Johnson ES; Cregeen RJ
Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
[TBL] [Abstract][Full Text] [Related]
36. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
37. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ
Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549
[TBL] [Abstract][Full Text] [Related]
38. Dose of urokinase for intracoronary thrombolysis in patients with acute myocardial infarction.
Ohyagi A; Hirose K; Watanabe Y; Nakai T; Tsujimoto S; Doyama K; Suzuki Y; Okazaki S; Hirai M
Clin Cardiol; 1987 Aug; 10(8):453-6. PubMed ID: 3621694
[TBL] [Abstract][Full Text] [Related]
39. Recanalization of Chronically Occluded Aortocoronary Saphenous Vein Bypass Grafts With Long-Term, Low Dose Direct Infusion of Urokinase (ROBUST): a serial trial.
Hartmann JR; McKeever LS; O'Neill WW; White CJ; Whitlow PL; Gilmore PS; Doorey AJ; Galichia JP; Enger EL
J Am Coll Cardiol; 1996 Jan; 27(1):60-6. PubMed ID: 8522711
[TBL] [Abstract][Full Text] [Related]
40. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
